share_log

Ducommun Incorporated Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Ducommun Incorporated Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Ducommun Incorporated 超出了分析師的預期:看看共識對今年的預測
Simply Wall St ·  02/18 07:21

Ducommun Incorporated (NYSE:DCO) shareholders are probably feeling a little disappointed, since its shares fell 2.2% to US$49.13 in the week after its latest yearly results. Ducommun reported US$757m in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of US$1.14 beat expectations, being 9.6% higher than what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Ducommun after the latest results.

杜康公司(紐約證券交易所代碼:DCO)的股東可能會感到有些失望,因爲其股價在公佈最新年度業績後的一週內下跌了2.2%,至49.13美元。Ducommun公佈的收入爲7.57億美元,與分析師的預測大致一致,儘管1.14美元的法定每股收益(EPS)超出預期,比分析師的預期高出9.6%。分析師通常會在每份收益報告中更新他們的預測,我們可以從他們的估計中判斷他們對公司的看法是否發生了變化,或者是否有任何新的問題需要注意。讀者會很高興得知我們已經彙總了最新的法定預測,以了解分析師在最新業績公佈後是否改變了對Ducommun的看法。

earnings-and-revenue-growth
NYSE:DCO Earnings and Revenue Growth February 18th 2024
紐約證券交易所:DCO 收益和收入增長 2024 年 2 月 18 日

Taking into account the latest results, the current consensus from Ducommun's five analysts is for revenues of US$797.6m in 2024. This would reflect a reasonable 5.4% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to jump 110% to US$2.30. Before this earnings report, the analysts had been forecasting revenues of US$812.6m and earnings per share (EPS) of US$2.36 in 2024. The analysts seem to have become a little more negative on the business after the latest results, given the small dip in their earnings per share numbers for next year.

考慮到最新業績,杜康蒙的五位分析師目前的共識是,2024年的收入爲7.976億美元。這將反映其收入在過去12個月中合理增長了5.4%。預計每股法定收益將增長110%,至2.30美元。在本業績發佈之前,分析師一直預測2024年的收入爲8.126億美元,每股收益(EPS)爲2.36美元。鑑於明年每股收益略有下降,分析師在最新業績公佈後似乎對該業務變得更加消極了。

The consensus price target held steady at US$64.80, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Ducommun, with the most bullish analyst valuing it at US$72.00 and the most bearish at US$58.00 per share. This is a very narrow spread of estimates, implying either that Ducommun is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

共識目標股價穩定在64.80美元,分析師似乎投票認爲,在可預見的將來,他們較低的預期收益預計不會導致股價下跌。但是,還有另一種思考價格目標的方法,那就是研究分析師提出的價格目標範圍,因爲範圍廣泛的估計可能表明,對業務可能的結果有不同的看法。對杜康的看法有所不同,最看漲的分析師將其估值爲72.00美元,最看跌的爲每股58.00美元。這與估計值的差距非常小,這意味着杜康曼是一家易於估值的公司,或者(更有可能)分析師嚴重依賴一些關鍵假設。

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Ducommun's past performance and to peers in the same industry. It's clear from the latest estimates that Ducommun's rate of growth is expected to accelerate meaningfully, with the forecast 5.4% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 2.0% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to see revenue growth of 6.5% annually. So it's clear that despite the acceleration in growth, Ducommun is expected to grow meaningfully slower than the industry average.

這些估計很有趣,但是在查看預測與杜科蒙過去的表現以及與同一行業的同行進行比較時,可以更粗略地描述一些細節。從最新估計中可以明顯看出,杜康的增長率預計將大幅加速,預計到2024年底的年化收入增長率爲5.4%,明顯快於過去五年中每年2.0%的歷史增長。相比之下,同行業的其他公司預計年收入將增長6.5%。因此,很明顯,儘管增長加速,但預計Ducommun的增長將明顯低於行業平均水平。

The Bottom Line

底線

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Ducommun. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$64.80, with the latest estimates not enough to have an impact on their price targets.

最大的擔憂是,分析師下調了每股收益的預期,這表明杜康蒙可能會面臨業務不利因素。從好的方面來看,收入估計沒有重大變化;儘管預測表明它們的表現將比整個行業差。共識目標股價穩定在64.80美元,最新估計不足以對其目標價格產生影響。

With that in mind, we wouldn't be too quick to come to a conclusion on Ducommun. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Ducommun analysts - going out to 2025, and you can see them free on our platform here.

考慮到這一點,我們不會很快就Ducommun得出結論。長期盈利能力比明年的利潤重要得多。多位Ducommun分析師估計,到2025年,你可以在我們的平台上免費查看。

Before you take the next step you should know about the 3 warning signs for Ducommun that we have uncovered.

在你採取下一步行動之前,你應該了解我們發現的Ducommun的3個警告信號。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論